title: N(omega) -nitro-L-arginine methyl ester (L-NAME) attenuates the acute inflammatory responses and brain injury during the early phase of experimental Escherichia coli meningitis in the newborn piglet.
abstract: We evaluated the anti-inflammatory and neuroprotective effect of nonselective NOS inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME), in experimental bacterial meningitis in the newborn piglet. Meningitis was induced by intracisternal injection of 10(8) colony forming units of Escherichia coli. L-NAME 10 mg kg(-1) was given intravenously 30 min before induction of meningitis. L-NAME significantly attenuated the increase in intracranial pressure and decrease in cerebrospinal fluid glucose concentration observed in the meningitis group. Systemic and cerebral perfusion pressure were even higher compared to the control and meningitis groups. However, the meningitis-induced increase in tumor necrosis factor-alpha level, leukocyte numbers and lactate level in the cerebrospinal fluid was not significantly attenuated with L-NAME administration. Reduced cerebral cortical cell membrane Na+, K+ -ATPase activity and increased lipid peroxidation products, indicative of meningitis-induced brain cell membrane dysfunction, were significantly improved with L-NAME treatment. Decreased brain glucose and ATP levels were also significantly improved with L-NAME treatment. These findings suggest that L-NAME was effective in attenuating the acute inflammatory responses and brain injury in neonatal bacterial meningitis.
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. wspark@smc.samsung.co.kr
authors.forename: W S
authors.initials: WS
authors.lastname: Park
authors.forename: Y S
authors.initials: YS
authors.lastname: Chang
authors.forename: M
authors.initials: M
authors.lastname: Lee
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001786:Blood Glucose; D001923:Brain Chemistry; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005947:Glucose / Q000032:analysis / Q000134:cerebrospinal fluid; D007427:Intracranial Pressure; D019344:Lactic Acid / Q000032:analysis / Q000097:blood / Q000134:cerebrospinal fluid; D007958:Leukocyte Count; D015227:Lipid Peroxidation; D020814:Meningitis, Escherichia coli / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism*; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology*; D009569:Nitric Oxide / Q000378:metabolism; D010108:Oxyhemoglobins / Q000378:metabolism; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D019265:Spectroscopy, Near-Infrared; D013552:Swine; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid
chemical_list: D001786:Blood Glucose; D004791:Enzyme Inhibitors; D010108:Oxyhemoglobins; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D019344:Lactic Acid; D000254:Sodium-Potassium-Exchanging ATPase; D005947:Glucose; D019331:NG-Nitroarginine Methyl Ester